Trial Profile
Phase II study of birinapant (TL32711) plus irinotecan in irinotecan-relapsed/refractory metastatic colorectal cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2013
Price :
$35
*
At a glance
- Drugs Birinapant (Primary) ; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- 19 Jun 2013 New trial record
- 02 Jun 2013 Results presented at 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO), according to a TetraLogic Pharmaceuticals media release.